Related Experiment Video
Updated: May 29, 2025

Production of Human CRISPR-Engineered CAR-T Cells
Published on: March 15, 2021
Blood cancer therapy with synthetic receptors and CRISPR technology
Haiying Zhang1, Mingxin Zhong1, Jingdong Zhang1
1Department of Hematology, Ganzhou People's Hospital, Ganzhou, Jiangxi 341000, China; Jiangxi Health Commission Key Laboratory of Leukemia, Ganzhou, Jiangxi 341000, China.
Abstract:
Chimeric antigen receptor (CAR)-T and -NK cells showed great success in treating hematological malignancies, including leukemia, lymphoma, and myeloma. CRISPR technology and other synthetic receptors (GPCR and synNotch) have helped to address some of the limitations and challenges associated with CAR-based therapies. Herein, this review aims to discuss how CAR can be integrated with other synthetic receptors and various CRISPR/Cas tools for blood cancer therapy. CAR-expressing cells equipped with other synthetic receptors can conditionally execute tumoricidal functions, prevent tumor escape from immune surveillance, and minimize non-tumor off-target toxicity. We also discussed how various CRISPR-Cas tools can be harnessed to enhance CAR cells functionality and persistence. The advances, pitfalls, and future perspectives for these synthetic receptors and CRISPR technology in blood cancer therapy are comprehensively discussed.
Related Concept Videos
CRISPR
Targeted Cancer Therapies
There are several types of targeted therapies against...
Homologous Recombination
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...

